Skip to main content
. 2022 Jul 8;29(7):4799–4810. doi: 10.3390/curroncol29070381

Figure 1.

Figure 1

Therapeutic response of atezolizumab plus bevacizumab. (a) Assessment of the therapeutic response at first CT or MRI imaging, based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) guidelines. (b) Assessment of the best overall re-sponse, based on RECIST 1.1 and modified RECIST guidelines. CR—complete response; PR—partial response; SD—stable disease; PD—progressive disease.